{"doi":"10.1093/cid/ciad560","title":"Rifampin Based Therapy for Patients With <i>Staphylococcus aureus</i> Native Vertebral Osteomyelitis: A Systematic Review and Meta-analysis","abstract":"BACKGROUND: Native vertebral osteomyelitis (NVO) caused by Staphylococcus aureus is associated with high risk of treatment failure and increased morbidity. The role of rifampin-based therapy for the treatment of this condition is controversial. The goal of this systematic review and meta-analysis is to explore the efficacy and safety of rifampin-based therapy for the treatment of S. aureus NVO. METHODS: We searched Cochrane, Embase, Medline, Scopus, and Web of Science databases for studies published up to May 2023, focusing on adults with NVO treated with or without rifampin-containing regimens. A random-effects model meta-analysis estimated relative risks and risk difference with 95% confidence intervals (CI). RESULTS: Thirteen studies (2 randomized controlled trials and 11 comparative cohort studies), comprising 244 patients with S. aureus NVO who received rifampin and 435 who did not, were analyzed. Meta-analysis showed that rifampin-based regimens were associated with lower risk of clinical failure (risk difference, -14%; 95% CI, -19% to -8%; P < .001; I2 = 0%; relative risk, 0.58; 95% CI, .37-.92, P = .02, I2 = 21%). Only 1 study reported on adverse events. All studies had a high or uncertain risk of bias, and the certainty of evidence was rated as very low. CONCLUSIONS: Adjunctive rifampin therapy might be associated with lower risk of S. aureus NVO treatment failure; however, the low certainty of evidence precludes drawing definitive conclusions that would alter clinical practice. A randomized trial is necessary to corroborate these findings.","journal":"Clinical Infectious Diseases","year":2023,"id":341641,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9577,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":631050,"name":"Elie F. Berbari","orcid":"0000-0001-9817-5391","position":1,"is_corresponding":false},{"id":1077620,"name":"Matteo Passerini","orcid":"0000-0002-8120-1853","position":2,"is_corresponding":false},{"id":1077621,"name":"Francesco Petri","orcid":"0000-0003-0125-9551","position":3,"is_corresponding":false},{"id":1077622,"name":"Julian Maamari","orcid":"0000-0002-6813-2179","position":4,"is_corresponding":false},{"id":56883,"name":"Mohammad Hassan Murad","orcid":"0000-0001-5502-5975","position":5,"is_corresponding":false},{"id":463410,"name":"Parham Sendi","orcid":"0000-0002-7347-6312","position":6,"is_corresponding":false},{"id":631047,"name":"Aaron J. Tande","orcid":"0000-0001-9775-7082","position":7,"is_corresponding":false},{"id":1077619,"name":"Said El Zein","orcid":"0000-0003-4331-5259","position":0,"is_corresponding":true}],"reference_count":56,"raw_metadata":null,"created_at":"2026-07-19T01:11:08.077724Z","pmid":"37721158","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}